Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T‐cell leukemia - Kawata, Takahito; Tada, Kohei; Kobayashi, Masayuki; Sakamoto, Takashi; Takiuchi, Yoko; Iwai, Fumie; Sakurada, Maki; Hishizawa, Masakatsu; Shirakawa, Kotaro; Shindo, Keisuke; Sato, Hironori; Takaori‐Kondo, Akifumi (Cancer science, 2018)
Keywords: adult T‐cell leukemia; Akt; Animals; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Everolimus - administration & dosage; Everolimus - pharmacology; HTLV‐1; Humans; Indoles - administration & dosage; Indoles - pharmacology; Leukemia-Lymphoma, Adult T-Cell - drug therapy; Leukemia-Lymphoma, Adult T-Cell - metabolism; Mechanistic Target of Rapamycin Complex 1 - antagonists & inhibitors; Mechanistic Target of Rapamycin Complex 2 - antagonists & inhibitors; Mice; Morpholines - administration & dosage; Morpholines - pharmacology; mTOR; mTORC; Original; Phosphorylation - drug effects; Purines - administration & dosage; Purines - pharmacology; RNA, Small Interfering - genetics; Signal Transduction - drug effects; Sirolimus - administration & dosage; Sirolimus - pharmacology; Xenograft Model Antitumor Assays; mTOR; HTLV-1; Akt; adult T-cell leukemia; mTORC